| Dr Satyam Arora, DO | |
|
1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 | |
| (610) 628-7920 | |
| (610) 821-2853 |
| Full Name | Dr Satyam Arora |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 15 Years |
| Location | 1901 Hamilton St, Allentown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275864431 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | OS016995 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Davita- St. Luke's Quakertown Dialysis | Quakertown, PA | Dialysis facility |
| Davita St. Luke's Bethlehem | Bethlehem, PA | Dialysis facility |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Lukes Quakertown Hospital | Quakertown, PA | Hospital |
| Geisinger St. Luke's Hospital | Orwigsburg, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gslpg, Inc | 7810226875 | 227 |
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.
GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.
Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.
› Verified 6 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.
GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.
Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.
› Verified 6 days ago
| Entity Name | Gslpg, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366006702 PECOS PAC ID: 7810226875 Enrollment ID: O20190917001763 |
News Archive
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.
GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.
Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Satyam Arora, DO 1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 Ph: (610) 628-7920 | Dr Satyam Arora, DO 1901 Hamilton St, Suite 300, Allentown, PA 18104-6459 Ph: (610) 628-7920 |
News Archive
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
Stereotaxis, Inc. announced today that it has been awarded $1.5 million in grants under the Qualifying Therapeutic Discovery Project Program that was enacted under the Patient Protection and Affordable Care Act of 2010.
GlycoMimetics, Inc. today announced top line clinical results from a Phase 2 study of GMI-1070 in patients experiencing vaso-occlusive crisis of sickle cell disease.
Additional investment in the world's 1.2 billion adolescents - 88 percent of whom live in the developing world - has the potential to help alleviate inequality and poverty, UNICEF said in its annual State of the World's Children report released on Friday, IRIN reports.
› Verified 6 days ago
Jessica Mary Boehmler, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 205, Allentown, PA 18103 Phone: 610-439-8856 Fax: 610-439-8856 | |
Allison Jane Baragona, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1501 N Cedar Crest Blvd Ste 110, Allentown, PA 18104 Phone: 610-821-2828 Fax: 610-821-7915 | |
James A Burke, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1250 S Cedar Crest Blvd, Suite 300, Allentown, PA 18103 Phone: 610-402-3110 Fax: 610-402-3112 | |
Stephen R Shore, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1901 Hamilton St Ste 300, Allentown, PA 18104 Phone: 610-628-7900 Fax: 833-816-7513 | |
Tarika Sejal Chowdhary, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 17th & Chew, Suite 101, Allentown, PA 18105 Phone: 610-969-4370 | |
Ashley Vojtek, DO Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1200 S Cedar Crest Blvd, Allentown, PA 18103 Phone: 484-862-3200 | |
Dr. Ian William Klansek, MD Nephrology Medicare: Medicare Enrolled Practice Location: 2490 Schoenersville Rd, Allentown, PA 18109 Phone: 484-526-7262 |